Literature DB >> 18566374

Stat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo.

Kotaro Sasaki1, Xi Zhao, Angela D Pardee, Ryo Ueda, Mitsugu Fujita, Sarita Sehra, Mark H Kaplan, Lawrence P Kane, Hideho Okada, Walter J Storkus.   

Abstract

VLA-4 plays a critical role in T cell trafficking into inflammatory sites. Our recent studies have suggested that VLA-4 expression on CD8+ T cells is negatively controlled by IL-4 and serves as a functionally distinguishing variable for why Type-1, but not Type-2, CD8+ T cells are able to traffic into tumors. In this study, using in vitro culture of murine CD8+ T cells under Type-1 and Type-2 cytokine conditions, we show that IL-4-mediated down-regulation of VLA-4 expression is completely abrogated in Stat6-deficient CD8+ T cells. Conversely, CD8+ T cells expressing a constitutively active mutant form Stat6 (Stat6VT) failed to express VLA-4 even in the absence of IL-4-stimulation. Notably, Type-2 CD8+ T cells developed from Stat6-/- but not wild-type mice were competent to migrate into tumor lesions in vivo. These results suggest that Stat6-signaling is necessary and sufficient to restrict CD8+ T cell expression of VLA-4 (by IL-4), thereby serving as a regulator for CD8+ T cell infiltration into tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18566374      PMCID: PMC2596982          DOI: 10.4049/jimmunol.181.1.104

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.

Authors:  R A Kemp; F Ronchese
Journal:  J Immunol       Date:  2001-12-01       Impact factor: 5.422

2.  Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis.

Authors:  T Chitnis; N Najafian; C Benou; A D Salama; M J Grusby; M H Sayegh; S J Khoury
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

3.  Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells.

Authors:  Shaik Ohidar Rahaman; Phyllis C Harbor; Olga Chernova; Gene H Barnett; Michael A Vogelbaum; S Jaharul Haque
Journal:  Oncogene       Date:  2002-12-05       Impact factor: 9.867

4.  IL-4 and IL-12 regulate proteoglycan-induced arthritis through Stat-dependent mechanisms.

Authors:  Alison Finnegan; Michael J Grusby; Charles D Kaplan; Shannon K O'Neill; Hermann Eibel; Tamas Koreny; Matyas Czipri; Katalin Mikecz; Jian Zhang
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

Review 5.  Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance.

Authors:  S Sakaguchi; N Sakaguchi; J Shimizu; S Yamazaki; T Sakihama; M Itoh; Y Kuniyasu; T Nomura; M Toda; T Takahashi
Journal:  Immunol Rev       Date:  2001-08       Impact factor: 12.988

6.  Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity.

Authors:  N Seo; S Hayakawa; M Takigawa; Y Tokura
Journal:  Immunology       Date:  2001-08       Impact factor: 7.397

Review 7.  IL-4/IL-13 signaling beyond JAK/STAT.

Authors:  H Jiang; M B Harris; P Rothman
Journal:  J Allergy Clin Immunol       Date:  2000-06       Impact factor: 10.793

8.  Expression of a constitutively active Stat6 in vivo alters lymphocyte homeostasis with distinct effects in T and B cells.

Authors:  Heather A Bruns; Ulrike Schindler; Mark H Kaplan
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

9.  Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors.

Authors:  Kotaro Sasaki; Xinmei Zhu; Cecilia Vasquez; Fumihiko Nishimura; Jill E Dusak; Jian Huang; Mitsugu Fujita; Amy Wesa; Douglas M Potter; Paul R Walker; Walter J Storkus; Hideho Okada
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

10.  Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.

Authors:  Tomohide Tatsumi; Lisa S Kierstead; Elena Ranieri; Loreto Gesualdo; Francesco P Schena; James H Finke; Ronald M Bukowski; Jan Mueller-Berghaus; John M Kirkwood; William W Kwok; Walter J Storkus
Journal:  J Exp Med       Date:  2002-09-02       Impact factor: 14.307

View more
  17 in total

Review 1.  Macrophages: Key orchestrators of a tumor microenvironment defined by therapeutic resistance.

Authors:  Kristen B Long; Arthur I Collier; Gregory L Beatty
Journal:  Mol Immunol       Date:  2017-12-19       Impact factor: 4.407

2.  Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.

Authors:  Anamika Bose; Jennifer L Taylor; Sean Alber; Simon C Watkins; Jorge A Garcia; Brian I Rini; Jennifer S Ko; Peter A Cohen; James H Finke; Walter J Storkus
Journal:  Int J Cancer       Date:  2011-05-25       Impact factor: 7.396

3.  Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.

Authors:  Anamika Bose; Devin B Lowe; Aparna Rao; Walter J Storkus
Journal:  Melanoma Res       Date:  2012-06       Impact factor: 3.599

4.  Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC.

Authors:  Hideho Okada; Lisa H Butterfield; Ronald L Hamilton; Aki Hoji; Masashi Sakaki; Brian J Ahn; Gary Kohanbash; Jan Drappatz; Johnathan Engh; Nduka Amankulor; Mark O Lively; Michael D Chan; Andres M Salazar; Edward G Shaw; Douglas M Potter; Frank S Lieberman
Journal:  Clin Cancer Res       Date:  2014-11-25       Impact factor: 12.531

Review 5.  Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.

Authors:  Pawel Kalinski; Hideho Okada
Journal:  Semin Immunol       Date:  2010-04-20       Impact factor: 11.130

Review 6.  The JAK/STAT signaling pathway: from bench to clinic.

Authors:  Xiaoyi Hu; Jing Li; Maorong Fu; Xia Zhao; Wei Wang
Journal:  Signal Transduct Target Ther       Date:  2021-11-26

7.  miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy.

Authors:  Kotaro Sasaki; Gary Kohanbash; Aki Hoji; Ryo Ueda; Heather A McDonald; Todd A Reinhart; Jeremy Martinson; Michael T Lotze; Francesco M Marincola; Ena Wang; Mitsugu Fujita; Hideho Okada
Journal:  J Transl Med       Date:  2010-02-18       Impact factor: 5.531

8.  PD-1 blockade enhances the vaccination-induced immune response in glioma.

Authors:  Joseph P Antonios; Horacio Soto; Richard G Everson; Joey Orpilla; Diana Moughon; Namjo Shin; Shaina Sedighim; William H Yong; Gang Li; Timothy F Cloughesy; Linda M Liau; Robert M Prins
Journal:  JCI Insight       Date:  2016-07-07

Review 9.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

10.  Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice.

Authors:  Yanjun Liu; Yibing Peng; Michael Mi; Jose Guevara-Patino; David H Munn; Ning Fu; Yukai He
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.